Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

Background: The phase IIIb CompLEEment-1 study evaluated ribociclib plus letrozole in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). Outcomes were investigated in the following subgroups: central nervous system (...

Full description

Bibliographic Details
Main Authors: Paul Cottu, Alistair Ring, Hikmat Abdel-Razeq, Paolo Marchetti, Fatima Cardoso, Javier Salvador Bofill, Miguel Martín, Lakshmi Menon-Singh, Jiwen Wu, Michelino De Laurentiis
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:Breast
Subjects:
Advanced breast cancer
Ribociclib
CDK4/6 inhibitor
Endocrine therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977622000236

Internet

http://www.sciencedirect.com/science/article/pii/S0960977622000236

Similar Items